Triiodothyronine as an adjunct to accelerate the antidepressant effects of the selective serotonin reuptake inhibitor (SSRI) escitalopram

Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine0 个研究点目标入组 60 人开始时间: 2007年3月16日最近更新: 2012年10月29日

适应症

试验速览

暂无简介。

•(1) Women, 18-60 years,
•(2) DSM-IV/ICD-10 diagnosis of single or recurrent non-psychotic major depressive disorder (MDD) 296.2–296.3/F32.1-F32-2.
•(3) Score of 20 or more on 17-item Ham-D scale.
•(4) Good physical health based on a physical examination, ECG and laboratory tests.
•(5) Signed Informed Consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•(1) Current DSM-IV/ICD-10 diagnosis of psychoses or dementia, as well as, mania, OCD, organic disorder, personality disorder.
•(2) DSM-IV/ICD-10 diagnosis of substance dependence within six month prior to screening.
•(3) Score of suicidality more than ten on the MINI.
•(4) Thyroid disease (including subclinical euthyroid autoimmune thyroid disease) or use of a thyroid hormone, antithyroid medication and amiodarone.
•(5) Known allergic reactions to SSRI or T3, history of serotoninergic syndrome.
•(6) ECT within three month before screening.
•(7) Pregnancy or breastfeeding.
•(8) Patients treated with fluexetine.

发起方

Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine